Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.56 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
| ▸ | NAE1 | Q13564 | 3/20 | 0.46 |
| ▸ | UBA3 | Q8TBC4 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | UBA6 | A0AVT1 | 1/20 | 0.44 |
| ▸ | ATG7 | O95352 | 1/20 | 0.44 |
| ▸ | UBA7 | P41226 | 1/20 | 0.44 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.44 |
| ▸ | FADS1 | O60427 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22524329 | 1.00 | AURKA (0.56) | AURKARPS6KB1EGFRAURKBNAE1 | |
| SCHEMBL22524270 | 0.81 | LRRK2 (0.40) | AURKARPS6KB1EGFRAURKBJAK2 | |
| SCHEMBL22524327 | 0.81 | LRRK2 (0.40) | AURKARPS6KB1EGFRAURKBJAK2 | |
| SCHEMBL24453689 | 0.81 | LRRK2 (0.40) | AURKARPS6KB1EGFRAURKBJAK2 | |
| SCHEMBL1798451 | 0.81 | FADS1 (0.45) | AURKARPS6KB1EGFRCA1CA2 | |
| SCHEMBL1797157 | 0.81 | CDK1 (0.48) | AURKARPS6KB1EGFRCA1CA2 | |
| SCHEMBL193515 | 0.81 | AURKA (0.57) | AURKARPS6KB1EGFRAURKBNAE1 | |
| SCHEMBL6746641 | 0.81 | AURKA (0.57) | AURKARPS6KB1EGFRAURKBNAE1 | |
| SCHEMBL19010820 | 0.79 | CDK1 (0.47) | AURKARPS6KB1EGFRCA1CA2 | |
| SCHEMBL22524325 | 0.78 | GAA (0.41) | AURKARPS6KB1EGFRAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162215-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ INC (US) | 2022-05-26 | — | — | US | disclosed |
| WO-2020206363-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ,INC. (US) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162215-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | NLN, PINK1, NME4 | AURKA 2173/4885RPS6KB1 955/4885EGFR 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.